Please confirm topic selection

Are you sure you want to trigger topic in your Anconeus AI algorithm?

Please confirm action

You are done for today with this topic.

Would you like to start learning session with this topic items scheduled for future?

Review Question - QID 101283

In scope icon M 3 E
QID 101283 (Type "101283" in App Search)
A 71-year-old man complains of urinary hesitancy and nocturia of increasing frequency over the past several months. Digital rectal exam was positive for a slightly enlarged prostate but did not detect any additional abnormalities of the prostate or rectum. The patient’s serum PSA was measured to be 6 ng/mL. Image A shows a transabdominal ultrasound of the patient. Which of the following medications should be included to optimally treat the patient's condition?
  • A

Clonidine

1%

2/148

Finasteride

94%

139/148

Dihydrotestosterone

1%

2/148

Diphenhydramine

1%

2/148

Furosemide

1%

1/148

  • A

Select Answer to see Preferred Response

bookmode logo Review TC In New Tab

This patient’s presentation is consistent with benign prostatic hyperplasia (BPH). Preferred medical treatment of BPH includes an alpha-1 adrenergic blocker (ex. tamsulosin) and/or a 5-alpha reductase inhibitor (ex. finasteride).

The prostate gland is located distal to the outflow tract of the bladder. Therefore, enlargement or hyperplasia of the prostate, especially in the periurethral transitional zone, presents with increased urinary hesitancy and frequency. 5-alpha reductase inhibitors act by inhibiting the conversion of testosterone to dihydrotestosterone, an important mediator of prostatic growth.

Edwards describes the management of BPH. The report states that for men with mild symptoms, watchful waiting with annual reassessment is most appropriate. If needed, alpha-blockers improve symptoms relatively quickly. Comparatively, 5-alpha reductase inhibitors have a slower onset of action but may in fact alter the disease course. Transurethral resection of the prostate (TURP) often provides permanent relief but has associated surgical complications including incontinence.

Cohen et al. review the efficacy of combination pharmacological treatment of BPH. Thy note that clinical trials of medical therapy for BPH have confirmed the finding that combined therapy with an a(1)-adrenergic receptor (AR) antagonist and a 5a-reductase inhibitor is superior to either agent alone.

Image A is a transabdominal ultrasound demonstrating enlargement of the prostate gland as seen in BPH. Illustration A shows the progression and consequences of BPH. Illustration B is an axial CT of BPH. Notice the prostate sits posterior to the pubic symphysis and anterior to the anal canal.

Incorrect Answers:
Answer 1: Clonidine is an alpha-2 adrenergic agonist, which would have the undesired effect of increasing urethral resistance to flow; this agent can be used to treat stress urinary incontinence. It is not indicated in the setting of BPH.

Answer 3: This would not improve BPH symptoms; in fact, it might have the opposite effect. Recall that finasteride, which prevents conversion of testosterone to dihydrotestosterone is effective in the setting of BPH.

Answer 4: Antihistamines should be avoided in patients with BPH.

Answer 5: As a diuretic, furosemide can worsen symptoms of BPH.

ILLUSTRATIONS:
REFERENCES (2)
Authors
Rating
Please Rate Question Quality

4.0

  • star icon star icon star icon
  • star icon star icon star icon
  • star icon star icon star icon
  • star icon star icon star icon
  • star icon star icon star icon

(4)

Attach Treatment Poll
Treatment poll is required to gain more useful feedback from members.
Please enter Question Text
Please enter at least 2 unique options
Please enter at least 2 unique options
Please enter at least 2 unique options